Rate My Professor Hiren Mandaliya

Dr. Hiren Mandaliya is a Conjoint Senior Lecturer in the School of Medicine and Public Health at the University of Newcastle. As a medical oncologist and Fellow of the Royal Australasian College of Physicians, he holds MBBS and MD degrees in Internal Medicine from Maharaja Sayajirao University, India. His career includes serving as Clinical Trial Fellow at Calvary Mater Newcastle in 2018, where he participated in multiple Phase I, Phase II, Phase III, and investigator-initiated trials. Since 2019, he has been Staff Specialist Medical Oncologist at Calvary Mater Newcastle and Visiting Medical Officer at Lake Macquarie Private Hospital and Newcastle Private Hospital. He regularly participates in multidisciplinary tumour board meetings at John Hunter Hospital and Calvary Mater Newcastle and maintains a strong commitment to medical education.

Dr. Mandaliya's research specializations encompass cancer research, with particular interests in lung cancer, mesothelioma, gynaecological cancers (ovarian, endometrial, cervical), breast cancers, melanoma, gastrointestinal, genitourinary, and head and neck cancers. He explores prognostic and predictive biomarkers in colon and lung cancers, conducts clinical trials for breast, lung, gastrointestinal, and other malignancies, and investigates psychosocial aspects of cancer survivors and medical students’ education. He collaborates on projects with scientists at Calvary Mater Newcastle, University of Newcastle, and Hunter Medical Research Institute. He received the Conquer Cancer Foundation of ASCO Merit Award in 2019 for his work on immunotherapy-related mortality. Key publications include Navani et al., "Melanoma: An immunotherapy journey from bench to bedside" (2022); Navani et al., "Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers" (2021, Cancer Research); Mandaliya et al., "Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)" (2020); and Williams et al., "Factors associated with adverse cardiovascular events in cancer patients treated with Bevacizumab" (2020).